ImageneBio Inc
$5.63
+1.3%Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -0.5).
Valuation inputs: P/E -0.5, earnings yield N/A, momentum +1.3%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -34.1%, ROIC -33.4%).
Profitability stack: net margin -56.7%, ROE -34.1%, ROIC -33.4%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +13.0%, momentum +1.3%, net margin -56.7%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
ImageneBio Inc Market vs Earnings Trajectory
Loading price and EPS data...
ImageneBio Inc Fair Value Envelope
ImageneBio Inc Profit Bridge
Profitability Analysis
Gross Margin
Negative gross margin indicates the company is losing money on each sale—unsustainable long-term.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
ImageneBio Inc Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
FCF Growth Trend
Flat FCF growth. Stable but not expanding—monitor for signs of business maturity or temporary headwinds.
Working Capital Impact
Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
ImageneBio Inc Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
ImageneBio Inc Street Expectations Map
Wall Street analysts project that IMA stock may decline over the coming 12 months. The consensus 1-year price target stands at 1.33, with estimates ranging from a low of 1.33 to a high of 1.33.
The consensus 1-year price target stands at 1.33, with estimates ranging from a low of 1.33 to a high of 1.33.
Analyst Consensus Analysis
Upside Potential
Significant downside risk. Stock trading well above analyst consensus suggests elevated valuation concerns and potential correction.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Risk-Reward Profile
Balanced risk-reward. Upside and downside potential relatively symmetric. Suitable for moderate risk tolerance with conviction in thesis.
Analyst Conviction
Bearish or uncertain outlook. Limited upside or poor consensus suggests challenges ahead or fundamental concerns.
Market Sentiment Insight
Consensus overvaluation: Analysts agree the stock is richly valued with limited upside. Consider booking profits or defensive positioning unless you have contrarian conviction in unrecognized catalysts.
ImageneBio Inc Insider Positioning
During the last 12 months, insiders have purchased $304K and sold $141K worth of IMA shares, resulting in $164K of net buying activity.
3 Months
384.7K
384.00
0
0.00
+384
+$384
3-6 Months
16.0K
95.84K
0
0.00
+96K
+$96K
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
83.6K
208.19K
39.7K
140.77K
+67K
+$67K
Top Buyers
Orbimed Advisors Llc
Director
$208K
Slattery Joseph P
Director
$96K
Bonita David P
Director
$384
Top Sellers
Marango Jotin
Officer: Chief Financial Officer
$79K
Bonita David P
Director
$31K
Stampacchia Otello
Director
$31K
Insider Activity Analysis
Net Insider Sentiment
Positive insider sentiment with $164K net buying. Buying activity substantially exceeds selling, indicating insider confidence.
Buy/Sell Ratio
Strong buy/sell ratio. Buying is at least double the selling activity, suggesting robust insider confidence.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
3 insider buyers and 3 sellers. Equal participation suggests mixed or neutral insider views.
Insider Activity Insight
Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.
No Dividend Yield Data
IMA has not reported any dividend yield values in the available annual periods.
ima Dividend History
Learning Layer
Related Guides
Build conviction on IMA by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.